alfuzosin has been researched along with Hypertension in 16 studies
alfuzosin: structure given in first source
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to assess the efficacy and safety of alfuzosin 10 mg monotherapy or combined antihypertensive medication on blood pressure (BP) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS) with or without antihypertensive medication." | 9.20 | Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive med ( Chung, WS; Hyun, JS; Kim, SW; Lee, SW; Min, KS; Moon, DG; Moon, KH; Park, JK; Park, K; Ryu, JK; Yang, DY; Yang, SK; Zhang, LT, 2015) |
| "To assess the efficacy and safety, and determine the optimal dosage, of a once-daily (OD) formulation of the clinically uroselective alpha(1)-blocker, alfuzosin, in patients with lower urinary tract symptoms and symptomatic benign prostatic hyperplasia." | 9.09 | Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. ( Roehrborn, CG, 2001) |
| "The new alpha 1-blocker alfuzosin was compared with propranolol as monotherapy for hypertension in a double-blind, parallel group study of 8-week duration in 40 patients with essential hypertension." | 9.07 | Comparison of the new alpha 1-blocker alfuzosin with propranolol as first-line therapy in hypertension. ( Antonacci, A; Bombelli, M; Leto di Priolo, S; Libretti, A; Marazzi, ME; Pirrelli, A; Sega, R; Vulpis, V, 1991) |
| "Alfuzosin did not cause any significant change in supine or upright heart rate." | 5.27 | Dose-titration study of alfuzosin, a new alpha 1-adrenoceptor blocker, in essential hypertension. ( Cazor, JL; Cocco, G; Leto di Priolo, S; Priore, P; Sfrisi, C, 1988) |
| "The objective of this study was to assess the efficacy and safety of alfuzosin 10 mg monotherapy or combined antihypertensive medication on blood pressure (BP) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS) with or without antihypertensive medication." | 5.20 | Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive med ( Chung, WS; Hyun, JS; Kim, SW; Lee, SW; Min, KS; Moon, DG; Moon, KH; Park, JK; Park, K; Ryu, JK; Yang, DY; Yang, SK; Zhang, LT, 2015) |
| "To assess the efficacy and safety, and determine the optimal dosage, of a once-daily (OD) formulation of the clinically uroselective alpha(1)-blocker, alfuzosin, in patients with lower urinary tract symptoms and symptomatic benign prostatic hyperplasia." | 5.09 | Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. ( Roehrborn, CG, 2001) |
| "Two placebo-controlled studies involving 588 patients (292 receiving SR alfuzosin 5 mg twice daily and 296 a placebo) were pooled; 51% of the patients were > or = 65 years of age and 43% had associated cardiovascular disease including hypertension and/or were receiving concomitant antihypertensive drugs." | 5.08 | Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. ( Buzelin, JM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Roth, S; Santoni, JP, 1997) |
| "The new alpha 1-blocker alfuzosin was compared with propranolol as monotherapy for hypertension in a double-blind, parallel group study of 8-week duration in 40 patients with essential hypertension." | 5.07 | Comparison of the new alpha 1-blocker alfuzosin with propranolol as first-line therapy in hypertension. ( Antonacci, A; Bombelli, M; Leto di Priolo, S; Libretti, A; Marazzi, ME; Pirrelli, A; Sega, R; Vulpis, V, 1991) |
| "To evaluate risk factors (hypertension, diabetes mellitus, and current tamsulosin, alfuzosin, terazosin, or doxazosin use) for intraoperative floppy iris syndrome (IFIS) in patients undergoing phacoemulsification cataract surgery." | 4.87 | Risk factors for intraoperative floppy iris syndrome: a meta-analysis. ( Chatziralli, IP; Sergentanis, TN, 2011) |
| "Alfuzosin (10 mg) OD is effective and well tolerated, and it has marginal effects on blood pressure, including in elderly patients and those with hypertension, ischemic heart disease or diabetes and those receiving antihypertensive agents." | 3.73 | Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, J, 2006) |
| "Tamsulosin has selectivity for the a alpha(1) and alpha(1d) receptor subtypes." | 2.42 | Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. ( Lowe, FC, 2004) |
| "Doxazosin GITS treatment resulted in optimal management of BP within the normal range, especially in pharmacologically or physiologically hypertensive patients." | 1.36 | Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension. ( Chung, BH; Lee, SH; Mah, SY; Park, KK, 2010) |
| "Alfuzosin did not cause any significant change in supine or upright heart rate." | 1.27 | Dose-titration study of alfuzosin, a new alpha 1-adrenoceptor blocker, in essential hypertension. ( Cazor, JL; Cocco, G; Leto di Priolo, S; Priore, P; Sfrisi, C, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Leeuw, PW | 1 |
| de Bos, R | 1 |
| van Soest, GA | 1 |
| Willemse, PJ | 1 |
| Birkenhäger, WH | 1 |
| Ohyama, K | 1 |
| Hori, Y | 1 |
| Sugiura, M | 1 |
| Zhang, LT | 1 |
| Lee, SW | 1 |
| Park, K | 1 |
| Chung, WS | 1 |
| Kim, SW | 1 |
| Hyun, JS | 1 |
| Moon, DG | 1 |
| Yang, SK | 1 |
| Ryu, JK | 1 |
| Yang, DY | 1 |
| Moon, KH | 1 |
| Min, KS | 1 |
| Park, JK | 1 |
| Lee, SH | 1 |
| Park, KK | 1 |
| Mah, SY | 1 |
| Chung, BH | 1 |
| Chatziralli, IP | 1 |
| Sergentanis, TN | 1 |
| Lowe, FC | 1 |
| Hartung, R | 1 |
| Matzkin, H | 1 |
| Alcaraz, A | 1 |
| Emberton, M | 1 |
| Harving, N | 1 |
| van Moorselaar, J | 1 |
| Elhilali, M | 1 |
| Vallancien, G | 1 |
| Cheung, CM | 1 |
| Awan, MA | 1 |
| Peh, KK | 1 |
| Sandramouli, S | 1 |
| Buzelin, JM | 1 |
| Delauche-Cavallier, MC | 1 |
| Roth, S | 1 |
| Geffriaud-Ricouard, C | 1 |
| Santoni, JP | 1 |
| Zabala, S | 1 |
| Thomson, C | 1 |
| Valdearcos, S | 1 |
| Gascón, A | 1 |
| Pina, MA | 1 |
| Michel, MC | 1 |
| Flannery, MT | 1 |
| Narayan, P | 1 |
| Roehrborn, CG | 1 |
| Chess-Williams, R | 1 |
| Sega, R | 1 |
| Marazzi, ME | 1 |
| Bombelli, M | 1 |
| Vulpis, V | 1 |
| Antonacci, A | 1 |
| Leto di Priolo, S | 2 |
| Pirrelli, A | 1 |
| Libretti, A | 1 |
| Priore, P | 1 |
| Cocco, G | 1 |
| Sfrisi, C | 1 |
| Cazor, JL | 1 |
| Manoury, PM | 1 |
| Binet, JL | 1 |
| Dumas, AP | 1 |
| Lefèvre-Borg, F | 1 |
| Cavero, I | 1 |
4 reviews available for alfuzosin and Hypertension
| Article | Year |
|---|---|
Risk factors for intraoperative floppy iris syndrome: a meta-analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Diabetes Complications; Doxazosin; Humans; Hypertension; In | 2011 |
Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Hum | 2004 |
Worldwide experience with alfuzosin and tamsulosin.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Controlled Clinical Trials as Topic; Hu | 2001 |
The use of alpha-adrenoceptor antagonists in lower urinary tract disease.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Sulfo | 2002 |
4 trials available for alfuzosin and Hypertension
8 other studies available for alfuzosin and Hypertension
| Article | Year |
|---|---|
Effect of sympathetic stimulation on inactive renin.
Topics: Acoustic Stimulation; Adrenergic alpha-Antagonists; Adult; Atenolol; Blood Pressure; Enzyme Precurso | 1982 |
Evaluation of syncope association with α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; Humans; Hypertension; Indoles; Male; Midd | 2019 |
Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Doxazosin; Drug Combina | 2010 |
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Antihypertensive Agents; Cardiovascular Diseases; D | 2006 |
Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha1-adrenoceptor antagonist.
Topics: Administration, Topical; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adul | 2007 |
Alfuzosin-induced hepatotoxicity.
Topics: Acute Disease; Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Humans; Hypertension | 2000 |
Dose-titration study of alfuzosin, a new alpha 1-adrenoceptor blocker, in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Dose-Response Relationship, Drug; Female; Heart | 1988 |
Synthesis and antihypertensive activity of a series of 4-amino-6,7-dimethoxyquinazoline derivatives.
Topics: Animals; Chemical Phenomena; Chemistry; Hypertension; Male; Quinazolines; Rats; Rats, Inbred SHR; St | 1986 |